Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2283575
Reference Type
Journal Article
Title
Sodium butyrate and short chain fatty acids in prevention of travellers' diarrhoea: A randomized prospective study
Author(s)
Krokowicz, L; Kaczmarek, BF; Krokowicz, P; Stojcev, Z; Mackiewicz, J; Walkowiak, J; Drews, M; Banasiewicz, T
Year
2014
Is Peer Reviewed?
1
Journal
Travel Medicine and Infectious Disease
ISSN:
1477-8939
Volume
12
Issue
2
Page Numbers
183-188
Language
English
PMID
24063909
DOI
10.1016/j.tmaid.2013.08.008
Abstract
INTRODUCTION:
Travellers' diarrhoea (TD) remains a considerable concern among international travellers. Known methods of prevention include dietary precautions, administration of vaccines and antibiotic agents.
AIM:
To assess the efficacy of sodium butyrate (SB) and short-chain fatty acids (SCFA) in prevention of TD.
MATERIAL AND METHODS:
67 adult patients planning to travel to subtropical countries were originally enrolled in the study. After eliminating 7 patients for not fulfilling the inclusion criteria, 60 patients were randomized into a study group receiving SB with SCFA and a placebo group. Patients were requested to complete previously distributed questionnaire daily. After elimination of 18 patients who did not return questionnaires, 42 patients completed the study (22 study, 20 placebo).
RESULTS:
In comparison to the control arm, the study arm noted significantly reduced occurrence of TD (4.5% vs. 40%, p = 0.008), was associated with a significant decrease in number of stools per day in travellers (1.9 vs. 4.2, p = 0.04), as well as a decrease in gastrointestinal symptoms including pain, bloating and nausea with fevers (0.7 vs. 1.4, p = 0.01). We recorded a trend towards decrease in diarrhoea related utilization of medical care in subjects from the study arm. There were no adverse effects noted regarding the use of SB and SCFA.
CONCLUSIONS:
Administration of SB with SCFA decreases occurrence of travellers' diarrhoea. It is safe and may constitute a new method of travellers' diarrhoea prevention.
Tags
IRIS
•
n-Butanol
Database searches
Pubmed
Database Searches - March 2014 (private)
Pubmed - 3/2014
Excluded (not pertinent)
Miscellaneous
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity